Claims
- 1. A method of determining a site of inflammation in a patient, comprising the steps of:
- administering to a patient an effective amount of an ELAM-1 ligand attached to a detectable label wherein the ELAM-1 ligand comprises a disaccharide or repeating disaccharide unit, a fucose residue connected at its 1-position to a disaccharide unit and a sialic acid residue connected to a terminal disaccharide unit;
- allowing the labeled ELAM-1 ligand sufficient time to circulate in the patient and attach to ELAM-1 in the patient; and
- detecting the label and its location in the patient and thereby determining the site of inflammation.
- 2. The method is claimed in claim 1, wherein the label is radioactive label.
- 3. The method as claimed in claim 1, wherein the ligand includes a single disaccharide unit in the form of Gal.beta.1.fwdarw.4GlcNAc.
- 4. The method as claimed in claim 3, wherein the fucose is connected at its 1-position of the 3-position of the GlcNAc.
- 5. The method as claimed in claim 4, wherein the sialic acid residue is an N-acetyl neuraminic acid connected at its 2-position to the 3-position of the Gal.
- 6. A method of determining a site of inflammation in a patient, comprising the steps of:
- administering to a patient an effective amount of an ELAM-1 ligand attached to a detachable label, wherein the ELAM-1 ligand has the following general structural formula: ##STR8## wherein one of A and B is hydrogen and one is an N-acetyl neuraminic acid residue; D and E are each independently hydrogen or a fucose residue; n is an integer of from 0 to 10 with the proviso that if n is O, E is a fucose residue; F is hydrogen, a lactosylceramide residue or a linking group;
- allowing the labeled ELAM-1 ligand sufficient time to circulate tin the patient and attach to ELAM-1 in the patient; and
- detecting the label and its location in the patient and thereby determining the site of inflammation.
- 7. The method as claimed in claim 6, wherein n is 0 and E is a fucose residue.
- 8. A method of determining a site of inflammation in a patient, comprising the step of:
- administering to a patient an effective amount of an ELAM-1 ligand attached to a detectable lable, wherein the ELAM-1 ligand has the following general structural formula: ##STR9## wherein one of A and B is hydrogen and one is an N-acetyl neuraminic acid residue, and F is a linking group;
- allowing the labeled ELAM-1 ligand sufficient time to circulate in the patient and attach to ELAM-1 in the patient; and
- detecting the label and its location in the patient and thereby determining the site of inflammation.
- 9. The method as claimed in claim 8, wherein the detectable label is a radioactive label.
CROSS-REFERENCE
This application is a continuation-in-part of our earlier filed application Ser. No. 07/613,113, filed Nov. 15, 1990, which is a continuation-in-part of our earlier filed application Ser. No. 07/559,856, filed on July 30, 1990, both of which applications are incorporated herein by reference and to which applications we claim priority under 35 USC .sctn.120.
Foreign Referenced Citations (1)
Number |
Date |
Country |
9013300 |
Nov 1990 |
WOX |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
613113 |
Nov 1990 |
|
Parent |
559856 |
Jul 1990 |
|